TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces first dosing of asthma patients with Voriconazole Inhalation Powder in a Ph.1b clinical trial for the treatment of IPA.

TFF Pharmaceuticals Announces First Dosing of Asthma Patients with Voriconazole Inhalation Powder in a Phase 1b Clinical Trial

AUSTIN, Texas--(BUSINESS WIRE)-- #Jefferies--TFF Pharmaceuticals to present at the Jefferies Virtual London Healthcare Conference, with a corporate presentation on November 19, at 2:55 PM ET.

TFF Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q3 2020 Results - Earnings Call Transcript

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals reports third quarter 2020 financial and business results - Conference call today, Thursday, November 5, 2020 at 4:30pm ET

TFF Pharmaceuticals Reports Third Quarter 2020 Financial and Business Results

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals and Felix Biotechnology sign Letter of Intent for a Collaboration, Development and License Agreement for bacteriophage therapies.

TFF Pharmaceuticals and Felix Biotechnology Sign Letter of Intent for a Collaboration, Development and License Agreement

AUSTIN, Texas & MENLO PARK, Calif.--(BUSINESS WIRE)--TFF Pharmaceuticals and Augmenta Bioworks enter into a worldwide joint development agreement for COVID-19 monoclonal antibody therapies.

TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces third quarter 2020 financial results and business update conference call on November 5, 2020.

TFF Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 5, 2020

TFF possess the rights to a game-changing drug formulation technology. They have a cost-efficient, fast route to market for their improved drugs.

TFF Pharmaceuticals - Game-Changing Drug Reformulation Technology

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces positive preclinical results with University of Georgia universal influenza vaccines.

TFF Pharmaceuticals Announces Positive Preclinical Results with University of Georgia Universal Influenza Vaccines

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals expands its cGMP manufacturing capabilities with Experic by installing a Thin Film Freezing processing line.

TFF Pharmaceuticals Expands its cGMP Manufacturing Capabilities with Experic

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals updates progress of human clinical trial with Tacrolimus Inhalation Powder for prevention of lung transplant rejection.

TFF Pharmaceuticals Updates Progress of Human Clinical Trial with Tacrolimus Inhalation Powder

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces results of its 2020 Annual Meeting of Stockholders

TFF Pharmaceuticals Announces Results of Its 2020 Annual Meeting of Stockholders

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals comments on animal studies in the development of high potency remdesivir as a dry powder for inhalation by Thin Film Freezing.

TFF Pharmaceuticals Comments on Animal Studies in the Development of High Potency Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals (NASDAQ: TFFP) announces topline results of Voriconazole Inhalation Powder Phase 1 clinical trial.

TFF Pharmaceuticals Announces Topline Results of Voriconazole Inhalation Powder Phase 1 Clinical Trial

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals to participate in Anti-fungal Webinar presented by Maxim Group LLC on September 17th, 2020

TFF Pharmaceuticals to Participate in Anti-fungal Webinar Presented by Maxim Group LLC on September 17th, 2020

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) will present at the H.C.

TFF Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

BMC Stock Hlds

Salesforce

Live Oak Bancshares

Liquidity Services

With Wall Street set to see its best August in 36 years on coronavirus cure optimism, Fed's plan to keep rates low and upbeat consumer confidence put spotlight on stocks with best month-to-date gains.

Wall Street Heads for Best August in 36 Years: 5 Top Gainers

TFF Pharmaceuticals: Undervalued Novel Drug Manufacturing Technique

TFF Pharmaceuticals (NASDAQ: TFFP) shares are trading higher after the company on Thursday reported a global licensing deal with UNION therapeutics for its Thin Film Freezing technology in combination with niclosamide.

Why TFF Pharmaceuticals Is Trading Higher Today

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q2 2020 Results - Earnings Call Transcript

HELLERUP, Denmark, Aug. 13, 2020 /PRNewswire/ -- Niclosamide identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir UNION has advanced niclosamide-based program for COVID-19 (UNI911) to clinical development, currently in Phase 1.

UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals in worldwide licensing agreement with UNION therapeutics for its Thin Film Freezing technology in combination with niclosamide.

TFF Pharmaceuticals Enters into Worldwide Licensing Agreement with UNION therapeutics for its Thin Film Freezing Technology in Combination with niclosamide

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals (NASDAQ:TFFP) reports second quarter 2020 financial and business results - Conference call today at 4:30 PM ET

TFF Pharmaceuticals Reports Second Quarter 2020 Financial and Business Results

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), announces $25.9 million in private financing to further advance its Thin Film Freezing technology platform.

TFF Pharmaceuticals Announces $25.9 Million in Financing to Further Advance Its Thin Film Freezing Technology Platform

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), it will release its second quarter 2020 financial results on August 13, 2020 at 4:00 PM ET.

News for TFF Pharmaceuticals Stock (TFFP)